☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Hansa Biopharma
Hansa Biopharma Reports First Patient Treatment of Imlifidase in P-II Study for ANCA-Associated Vasculitis
July 19, 2023
Hansa Biopharma Receives Positive Reimbursement Decision for Idefirix (imlifidase) in the Czech Republic
January 2, 2023
Hansa Biopharma's Idefirix (imlifidase) Receives NICE Recommendation as Desensitization Treatment for Highly Sensitized Kidney Tra...
June 16, 2022
Hansa Biopharma Signs an Agreement with AskBio to Evaluate Imlifidase as Pre-Treatment in Pompe Disease
January 4, 2022
Hansa Biopharma Reports First Patient Enrollment in (ConfIdeS) Trial of Imlifidase for the Treatment of Patients with Kidney Trans...
December 29, 2021
Load more...
Back to Home